The production of IgGs has revolutionized the biotech industry with products used for the treatment ofcancer and immune disorders. IgGs represent just one potential class of biotherapeutic and yet few otherclasses (with potential to treat specific diseases) have been as well developed due to challenges in theirmanufacture. Challenging new recombinant proteins (rPs) of commercial and clinical value include fusionproteins (for novel disease targeting), IgA (the most abundant Ig isoform, for treatment of IgAdeficiencies, cancer) and secreted mucins (for disease therapy, vaccines). This project will develop newanimal (CHO) and plant (tobacco) cell and glycosylation expression technologies, and establishbioprocesses, for the production of these difficult to express novel rPs that have the potential to open upnew targets and treatments that resist current therapies. The consortium will seek protection of IP rightsfor the new technologies and to develop these with interested parties.